Maghreb Edition

North Africans rush to Sanofi, betting on its antimalarials to fight Covid-19F

Posted On 26 March 2020

Number of times this article was read : 451

The Algerian Minister of Health, Population and Hospital Reform announced on 23 March the use of a drug to treat patients proven to carry the Covid-19 virus. “Based on the experience of some countries, Algeria’s top scientific committee decided to implement a new treatment protocol, based on a drug both produced  locally and imported. It will be prescribed in confirmed cases and it is available in sufficient quantities,” said health minister Abderrahmane Benbouzid in a state TV interview. The minister did not give more details on the drug, but the note sent by the ministry to the directorates of health and populations indicates that it is indeed Chloroquine, a drug already used by several countries.

Officials at the Ministry of Health said Algeria has begun negotiations with two pharmaceutical groups, the French Sanofi and the Jordanian Hikma, to order large quantities of drugs made from the chloroquine to treat patients the COVID-19 virus. On the ground, Dr. Bekkat Berkani, President of the Council of the Order of Doctors said treatment using chloroquine has already begun at El Kettar Hospital and that it will take several days to get some preliminary results. (Source MEA Risk LLC)

And in Morocco

Rabat, March 24, 2020 (AFP) – Morocco has authorised hospitals to use antimalarial drugs in treating the new coronavirus, according to a document seen by AFP, as scientists urge caution over encouraging results from small trials. The Moroccan health ministry on Monday gave hospitals and regional health directors the green light to start using hydroxychloroquine and related compound chloroquine “in the care of confirmed COVID-19 cases”.
In a message seen by AFP, it said that “efforts have been made to ensure the availability of these medicines”, urging caution in how the stocks are managed.

Rabat last week ordered the Moroccan branch of French drug maker Sanofi to hand over its entire stock of Nivaquine and Plaquenil, both of which contain chloroquine. Studies in France and China have found that the drug helped patients suffering from the COVID-19 illness, and France on Monday ordered its use in severe cases. US President Donald Trump on Monday said chloroquine could be a “gift from God”. He has been criticised by scientists for overhyping the drug, and on Monday the World Health Organization urged caution over its use. BC later reported that a woman in Arizona who heard Trump talk about chloroquine ended up in hospital and her husband died after they took a form of chloroquine she had used to treat her koi fish. Authorities in Nigeria said hospitals had seen cases of chloroquine poisoning after Trump’s comments.

Experts have urged the public to remain cautious until larger clinical trials validate the smaller studies. In its note, Morocco’s health ministry said it took its decision after consulting with a scientific committee which recommended prescribing chloroquine along with another drug called azithromycine. Morocco’s transport minister, Abdelkader Amara, who tested positive for the new coronavirus on March 14, has already said he was taking Nivaquine. “My health is stable. I have no fever or respiratory symptoms. The headaches are almost gone. I just feel a little tired,” he told private radio station Medi 1. Morocco has recorded 143 cases of the COVID-19 illness, with four dead. The country has three screening centres and 1,642 intensive care beds for 35 million inhabitants.

 

Subscribe to Urgent Notifications and Newsletter

Most Recent Stories from the Region

Gulf War Escalates as Energy Markets Reel and Regional Fronts Multiply$

The war involving Iran, Israel, and the United States is expanding across the Middle East, with growing consequences for global energy markets and regional security. Disruptions in the Strait of Hormuz and attacks on Gulf energy infrastructure have pushed oil prices higher and raised concerns about supply stability. As missile exchanges intensify and fighting spreads to Lebanon, world leaders are scrambling to assess the economic fallout and prevent further escalation.

West Africa: Jihadist Attacks Intensify in Northern Benin Amid Cross-Border Insurgency Pressure$

Jihadist attacks in northern Benin have intensified in recent weeks, with militants linked to JNIM claiming a deadly assault on a military position near the Niger border and carrying out additional raids on security posts along the country’s volatile frontiers with Burkina Faso and Nigeria. The violence underscores how northern Benin has become part of a wider cross-border insurgency spilling south from the central Sahel, even as authorities bolster Operation Mirador and try to prevent armed groups from entrenching themselves on Beninese soil.

Desert Locusts Stir Fresh Worries in North-West Africa$

Small desert locust swarms recently detected along the western Sahara corridor have prompted stepped-up monitoring across parts of North and West Africa, where shifting rainfall can quickly turn quiet desert areas into launchpads for wider infestations.

Written by The North Africa Journal

The North Africa Journal is a leading English-language publication focused on North Africa. The Journal covers primarily the Maghreb region and expands its general coverage to the Sahel, Egypt, and beyond, when events in those regions affect the broader North Africa geography. The Journal does not have any affiliation with any institution and has been independent since its founding in 1996. Our position is to always bring our best analysis of events affecting the region, and remain as neutral as humanly possible. Our coverage is not limited to one single topic, but ranges from economic and political affairs, to security, defense, social and environmental issues. We rely on our full staff analysts and editors to bring you best-in-class analysis. We also work with sister company MEA Risk LLC, to leverage the presence on the ground of a solid network of contributors and experts. Information on MEA Risk can be found at www.MEA-Risk.com.